Author: admin

  • Can zebrafish help humans regrow hearing cells?

    Can zebrafish help humans regrow hearing cells?

    While humans can regularly replace certain cells, like those in our blood and gut, we cannot naturally regrow most other parts of the body. For example, when the tiny sensory hair cells in our inner ears are damaged, the result is often permanent hearing loss, deafness, or balance problems. In contrast, animals like fish, frogs, and chicks regenerate sensory hair cells effortlessly.

    Now, scientists at the Stowers Institute for Medical Research have identified how two distinct genes guide the regeneration of sensory cells in zebrafish. The discovery improves our understanding of how regeneration works in zebrafish and may guide future studies on hearing loss and regenerative medicine in mammals, including humans.

    “Mammals such as ourselves cannot regenerate hair cells in the inner ear,” said Stowers Investigator Tatjana Piotrowski, Ph.D., the study’s co-author. “As we age or are subjected to prolonged noise exposure, we lose our hearing and balance.”

    New research from the Piotrowski Lab, published in Nature Communications on July 14, 2025, seeks to understand how cell division is regulated to both promote regeneration of hair cells and to also maintain a steady supply of stem cells. Led by former Stowers Researcher Mark Lush, Ph.D., the team discovered that two different genes regulating cell division each control the growth of two key types of sensory support cells in zebrafish. The finding may help scientists study whether similar processes could be triggered in human cells in the future.

    “During normal tissue maintenance and regeneration, cells need to proliferate to replace the cells that are dying or being shed — however, this only works if there are existing cells that can divide to replace them,” said Piotrowski. “To understand how proliferation is regulated, we need to understand how stem cells and their offspring know when to divide and at what point to differentiate.”

    Zebrafish are an excellent system for studying regeneration. Dotted in a straight line from their head to tailfin are sensory organs called neuromasts. Each neuromast resembles a garlic bulb with “hair cells” sprouting from its top. A variety of supporting cells encompass the neuromast to give rise to new hair cells. These sensory cells, which help zebrafish detect water motion, closely resemble those in the human inner ear.

    Because zebrafish are transparent during development and have accessible sensory organ systems, scientists can visualize, as well as genetically sequence and modify, each neuromast cell. This allows them to investigate the mechanisms of stem cell renewal, the proliferation of progenitor cells — direct precursors to hair cells — and hair cell regeneration.

    “We can manipulate genes and test which ones are important for regeneration,” said Piotrowski. “By understanding how these cells regenerate in zebrafish, we hope to identify why similar regeneration does not occur in mammals and whether it might be possible to encourage this process in the future.”

    Two key populations of support cells contribute to regeneration within neuromasts: active stem cells at the neuromast’s edge and progenitor cells near the center. These cells divide symmetrically, which allows the neuromast to continuously make new hair cells while not depleting its stem cells. The team used a sequencing technique to determine which genes were active in each type and found two distinct cyclinD genes present in only one or the other population.

    The researchers then genetically altered each gene in the stem and progenitor populations. They discovered that the different cyclinD genes were independently regulating cell division of the two types of cells.

    “When we rendered one of these genes non-functional, only one population stopped dividing,” said Piotrowski. “This finding shows that different groups of cells within an organ can be controlled separately, which may help scientists understand cell growth in other tissues, such as the intestine or blood.”

    Progenitor cells lacking their cell type-specific cyclinD gene did not proliferate; however, they did form a hair cell, uncoupling cell division with differentiation. Notably, when the stem cell-specific cyclinD gene was engineered to work in progenitor cells, progenitor cell division was restored.

    David Raible, Ph.D., a professor at the University of Washington who studies the zebrafish lateral line sensory system, commented on the significance of the new study. “This work illuminates an elegant mechanism for maintaining neuromast stem cells while promoting hair cell regeneration. It may help us investigate whether similar processes exist or could be activated in mammals.”

    Because cyclinD genes also regulate proliferation in many human cells, like those in the gut and blood, the team’s findings may have implications beyond hair cell regeneration.

    “Insights from zebrafish hair cell regeneration could eventually inform research on other organs and tissues, both those that naturally regenerate and those that do not,” said Piotrowski.

    Additional authors include Ya-Yin Tsai, Shiyuan Chen, Daniela Münch, Julia Peloggia, Ph.D., and Jeremy Sandler, Ph.D.

    This work was funded by the National Institute on Deafness and Other Communication Disorders of the National Institutes of Health (NIH) (award: 1R01DC015488-01A1), the Hearing Health Foundation, and with institutional support from the Stowers Institute for Medical Research. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

    Continue Reading

  • ‘Mismatched’ Transplants Now Safe for Blood Cancer Patients

    ‘Mismatched’ Transplants Now Safe for Blood Cancer Patients

    Advances in blood stem cell transplants now make it possible for people with blood cancers to get safe and effective “mismatched” transplants that will potentially cure their disease, new UVA Cancer Center research reveals. The advances will allow far more people to receive the lifesaving treatment.

    Patients who could not find a perfect match traditionally have not received transplants because of the potential for graft-versus-host disease. This occurs when the immune system recognizes the transplanted cells as foreign and attacks them. This can be serious and, in some cases, even deadly.

    The new study, however, found that a treatment approach using the drug cyclophosphamide can prevent most graft-versus-host disease. The researchers followed 145 patients who received the cyclophosphamide treatment and found that eight out of 10, or about 80%, were alive after a year. This is similar to the outcomes seen in studies of patients who receive fully matched transplants.

    “This study is important because all patients, regardless of background, now have a stem cell or bone marrow transplant donor, a significant advance for our field, our patients and our community,” said Karen Ballen, MD, UVA Health’s Chief of Hematology/Oncology and Medical Director of Stem Cell Transplant. “At UVA Health, in the past year, all eligible patients for stem cell transplant were able to find a suitably matched donor.” 

    About the Blood Cancer Study

    UVA’s Stem Cell Transplant Program was one of the main sites for the trial. Participants had leukemia, lymphoma or myelodysplastic syndrome and had been unable to find fully matched donors. They received a partially matched peripheral blood stem cell transplant and were given cyclophosphamide to prevent graft-versus-host disease.

    Among the patients who received cyclophosphamide, only 10% developed moderate to severe or chronic graft-versus-host disease. This is about the same percentage as among patients who receive fully matched donations.

    In a new scientific paper outlining their findings, the researchers describe the outcomes as “excellent” and call the addition of cyclophosphamide an “important advance.” 

    Findings Published

    The researchers have published their results in The Journal of Clinical Oncology. A full list of the researchers and their disclosures is included in the paper, which is free to read.

    The study was supported by the National Institutes of Health’s National Cancer Institute, grant U24CA076518; the National Heart, Lung and Blood Institute, grants U24CA076518 and UG1HL174426; the National Institute of Allergy and Infectious Diseases, grants U24CA076518 and U01AI184132; the Health Resources and Services Administration, grant 75R60222C00011; and the Office of Naval Research, grants N00014-24-1-2057 and N00014-25-1-2146.

    To keep up with the latest medical research news from UVA, subscribe to the Making of Medicine blog.

    Continue Reading

  • Toronto Favors Andretti Global, Chip Ganassi Racing

    Toronto Favors Andretti Global, Chip Ganassi Racing

    Alex Palou enters Sunday’s Ontario Honda Dealers Indy Toronto with a commanding 129-point lead over Pato O’Ward as the NTT INDYCAR SERIES heads into the fourth and final street race of the 2025 season.

    The duo split victories last weekend at Iowa Speedway, with O’Ward earning his first victory of the season in Saturday’s Synk 275 powered by Sukup while Palou captured his series-leading seventh win in Sunday’s Farm to Finish 275 powered by Sukup.

    Despite dominating this season, Palou has yet to win on Toronto’s 1.786-mile temporary street circuit. In three career starts, he has been eliminated in the opening round of qualifying each time, starting 22nd, 15th and 18th, respectively. But the three-time series champion has impressively raced through the field to finish sixth, second and fourth.

    On the other hand, O’Ward has struggled on street circuits in 2025. His average finish across the three prior street races is 10.33. In three Toronto appearances, the Arrow McLaren driver has finished 11th, eighth and 17th.

    Sunday’s 90-lap event could be a damage-mitigation race for O’Ward and his Chevrolet counterparts. His Iowa win marked the first win for Chevrolet this season while Honda has claimed 11 of the 12 races, including all three on street circuits and six of the nine podium finishes.

    This season’s street races began with Palou edging Chip Ganassi Racing teammate Scott Dixon in Firestone Grand Prix of St. Petersburg presented by RP Funding on March 2. Kyle Kirkwood then topped Palou in the Acura Grand Prix of Long Beach on April 13 and Santino Ferrucci’s No. 14 AJ Foyt Racing Chevrolet in the Chevrolet Detroit Grand Prix presented by Lear on June 1.

    Kirkwood leads all drivers with a 2.33 average finish on street circuits this season. However, a disastrous Iowa weekend, including a crash in practice and another crash in Race 1 – he finished 26th and 18th in the races — cost him 67 points and dropped him from second to fourth in the standings. He trails Palou by 180 points. On the bright side, Kirkwood finished runner-up to teammate Colton Herta (shown in photo) last year in Toronto.

    History favors CGR and Andretti Global this weekend. Their drivers swept the Toronto podium last year and have combined for nine of the last 12 top-three finishes at Exhibition Place. Gaining ground on Palou and Dixon in Round 13 of the 2025 season won’t be easy.

    Dixon’s seventh-place average finish on street courses this season ranks third behind Kirkwood and Christian Lundgaard (sixth-place average). Lundgaard, who is fifth in the standings, earned his only INDYCAR SERIES victory here in 2023 while driving for Rahal Letterman Lanigan Racing and with three consecutive top-eight finishes in Toronto eyes a second Arrow McLaren win in three races.

    The first practice in Toronto is 3:05 p.m. ET Friday on FS2, FOX Sports app and INDYCAR Radio Network. The series returns to the track at 10:30 a.m Saturday for the second practice session in advance of the three-round knockout NTT P1 Award qualifying session scheduled to begin at 2:35 p.m. Both Saturday sessions will air on FS1, FOX Sports app and INDYCAR Radio Network.

    Sunday’s schedule features the pre-race warmup at 8:30 a.m. ET (FS1, FOX Sports app and INDYCAR Radio Network) before the 90-lap race at noon on FOX, FOX Sports app and INDYCAR Radio Network.


    Continue Reading

  • How to Watch the 2025 Primetime Emmy Nominations Announcement Live

    How to Watch the 2025 Primetime Emmy Nominations Announcement Live

    Beyoncé, Ariana Grande, Selena Gomez and more music stars could become 2025 Primetime Emmy nominees. And you can find out if they make it or not at the very same moment they do – on Tuesday (July 15) at 11:30 a.m. ET/8:30 a.m. PT, when the Television Academy unveils the nominations for the 77th annual Primetime Emmy Awards.

    To watch the nominations livestream, head to this page on the Television Academy site or watch the livestream on YouTube.

    What We Do in the Shadows star Harvey Guillén and Running Point star Brenda Song will reveal the nominees alongside TV Academy chair Cris Abrego in a ceremony at the academy’s Wolf Theater in Los Angeles. (The ceremony is held at a much more civilized hour than the Oscar nominations reveal is each year. To watch that, West Coasters have to get up at 5:30 a.m. PT.)

    Beyoncé could be well-represented in the nominations. Her Netflix special Beyoncé Bowl has a good chance of being nominated for outstanding variety special (live), where it could face the 2025 Grammy Awards – where Queen Bey finally won her first award for album of the year.

    Cynthia Erivo and Ariana Grande, who were nominated for Oscars earlier this year for their performances in Wicked, could be competing against each other for outstanding guest actress in a comedy series. Erivo is eligible with Poker Face; Grande with Saturday Night Live.

    Selena Gomez is likely to be nominated for outstanding comedy series for the fourth year in a row as an executive producer of Only Murders in the Building. She could also be nominated for outstanding lead actress in a comedy series for the second year in a row.

    Many other programs featuring top music stars have a shot at nominations in various categories. An Evening With Elton John and Brandi Carlile could be nominated for outstanding variety special (pre-recorded). Road Diary: Bruce Springsteen and the E Street Band (Hulu) could be nominated for outstanding documentary special.

    The 2025 Primetime Emmy Awards are set to air on Sept. 14 at 8 p.m./5 p.m. PT on CBS and stream live and on demand on Paramount+. Comedian Nate Bargatze is set to host the show, which will be held at the Peacock Theater in downtown Los Angeles. Bargatze has yet to be nominated for a Primetime Emmy, but he was nominated for a Grammy in 2022 for best comedy album for The Greatest Average American.

    The September ceremony will be produced by Jesse Collins Entertainment (Jesse Collins, Dionne Harmon, and Jeannae Rouzan-Clay) for the third consecutive year.

    Continue Reading

  • Astronomers discover monster exoplanet hiding in ‘stellar fog’ around young star

    Astronomers discover monster exoplanet hiding in ‘stellar fog’ around young star

    Astronomers have spotted a monster-sized planet that could be up to ten times the size of Jupiter emerging from the stellar fog surrounding a young star.

    Prior observations of the roughly 13 million-year-old star MP Mus (also known as PDS 66) located around 280 light-years away had failed to distinguish features in the swirling cloud of gas and dust, or protoplanetary disk, that surrounds it.

    Continue Reading

  • SpaceX partners with Israel to launch Dror 1 satellite – The Jerusalem Post

    1. SpaceX partners with Israel to launch Dror 1 satellite  The Jerusalem Post
    2. Israel’s most-advanced communications satellite successfully launched into space  The Times of Israel
    3. Israel must fund national space strategy that balances defense, scientific goals – editorial  The Jerusalem Post
    4. Space Coast’s 60th launch of year also Falcon 9’s 500th successful SpaceX mission  The Spokesman-Review
    5. SpaceX launches mystery satellite to geostationary transfer orbit (video)  Yahoo News

    Continue Reading

  • CJP orders free legal aid for poor, urges reforms in backward districts – Samaa TV

    1. CJP orders free legal aid for poor, urges reforms in backward districts  Samaa TV
    2. CJP for meaningful coordination to enhance justice delivery  Associated Press of Pakistan
    3. Chief Justice Yahya Afridi arrives in Quetta on first official visit  Dunya News
    4. Supreme Court to commence hearing of cases at Quetta Registry from today  dailyindependent.com.pk

    Continue Reading

  • Analysts have raised their estimates on these stocks reporting this week

    Analysts have raised their estimates on these stocks reporting this week

    Continue Reading

  • New immunotherapy targets leukemia at its root

    New immunotherapy targets leukemia at its root

    Researchers at MUSC Hollings Cancer Center have identified a signaling loop involved in the growth and persistence of leukemia cells – and developed a novel immunotherapy that can disrupt that loop to boost immune function and improve survival. The findings, published in Nature Communications, offer new hope for treating and preventing cancer.

    Hollings researcher Sophie Paczesny, M.D., Ph.D., co-leader of the Cancer Biology and Immunology Research Program, led the multidisciplinary research team. Paczesny, a pediatric hematologist-oncologist and bone marrow transplant expert, has spent her career fighting one of the most difficult-to-treat blood cancers: acute myeloid leukemia (AML).

    I’ve seen too many patients – especially children – suffer from AML,” Paczesny said. “Unlike other forms of leukemia that respond well to chemotherapy or CAR-T cell therapy, AML has proven much more stubborn.”


    Sophie Paczesny, M.D., Ph.D., Hollings researcher

    A challenging diagnosis

    AML is a fast-growing and aggressive form of blood cancer. Even with treatment, the cancer often comes back. This high rate of relapse can be traced to leukemia stem cells, a small group of cells that can survive chemotherapy by hiding in the bone marrow. These “hidden” cells then send out signals that both help the cancer grow and prevent the immune system from fighting back.

    The new study revealed a key pathway used by these leukemia cells: the loop between a protein called IL-33 and its receptor IL1RL1. The researchers showed that IL1RL1, which is present in high amounts on AML cells and in the tumor’s protective environment, is key to its treatment resistance.

    “The more aggressive the leukemia, the more IL1RL1 we saw,” Paczesny said. “And, in AML, it forms a damaging feedback loop. The leukemia starts and keeps growing because of stress that triggers a self-sustaining loop between IL-33 and its receptor, which also creates an immune environment that helps the cancer avoid being attacked.”

    Breaking the loop

    To break the feedback loop, the researchers developed a novel immunotherapy using a lab-made antibody. Known as a bispecific antibody, the treatment worked via dual means:

    • It blocked the IL-33/IL1RL1 signal by targeting and killing leukemia cells carrying IL1RL1.



    • It prompted the immune system to attack the cancer cells by activating infection-fighting T-cells like CD8+.

    “These leukemia cells have learned to create a protective environment that helps them grow and avoid treatment,” Paczesny said. “We developed a bispecific antibody that can break through that environment and target the cells directly.”

    In lab and mouse models, this dual-targeting approach not only destroyed the cancer cells but also removed their protective immune bubbles, making it easier for the body to fight back. The antibody slowed or stopped leukemia cell growth, limited immune suppression and reduced relapse rates. Even in tough cases where leukemia had already taken hold, the new therapy improved survival. And it did so without causing major side effects.

    A new way forward

    This study showed that targeting the signaling pathway used by leukemia stem cells can lead to better care for cancer patients. The researchers created an immunotherapy that not only killed cancer cells but also disrupted the immune system’s ability to protect them. By blocking a hidden cancer signal, that therapeutic may one day stop leukemia in its tracks.

    The promising results offer an approach that could improve treatments for AML as well as other cancers with a similar tumor microenvironment.

    “IL1RL1 is expressed in other cancers too: colorectal, lung, ovarian, even brain cancers,” Paczesny said. “This could be a game-changer for many difficult-to-treat cancers.”

    The researchers also see the new antibody as overcoming some of the challenges of existing treatments. For instance, its low toxicity could make it safer to use and more acceptable to patients. It is also easier and less expensive to produce.

    “Chemotherapy is toxic, and bone marrow transplants can come with serious risks. With immunotherapies like CAR-T cells, you need a customized treatment for each patient, which is expensive and time-consuming,” Paczesny explained. “Our treatment is an off-the-shelf drug. And it targets cells just enough to fight cancer without destroying the whole system. This could mean less time in the hospital, fewer side effects and a better quality of life.”

    More work is needed before the antibody can be used with patients, but this study is a major step forward. It could eventually lead to new treatments that target cancer cells at their roots and offer an option when standard treatments fail. The researchers are already working on next steps and are hopeful that Phase I clinical trials are on the horizon.

    Source:

    Medical University of South Carolina

    Journal reference:

    Fu, D., et al. (2025). Dual targeting of tumoral cells and immune microenvironment by blocking the IL-33/IL1RL1 pathway. Nature Communications. doi.org/10.1038/s41467-025-61567-7.

    Continue Reading

  • Space Science Reviews Publishes TRACERS Article Collection | Physics and Astronomy – College of Liberal Arts and Sciences

    The journal Space Science Reviews is publishing a collection of articles about the University of Iowa-led Tandem Reconnection And Cusp Electrodynamics Reconnaissance Satellites (TRACERS) mission. This collection presents the science objectives of the mission, descriptions of the design and calibration of the plasma instruments, and other important aspects of the mission.

    Dr. David Miles, associate professor in the UI Department of Physics and Astronomy, is leading NASA-funded mission, which aims to uncover how magnetic reconnection drives dynamic processes in Earth’s cusp region—a critical gateway between the solar wind and our planet’s magnetosphere.

    TRACERS will use two identical small satellites flying in tandem low-Earth orbits to collect plasma and magnetic field data over a 12-month primary mission. These measurements will help scientists understand how spatial and temporal variations in reconnection influence the coupling between the solar wind and near-Earth space.

    An overview of the mission can be found in this article: The Tandem Reconnection and Cusp Electrodynamics Reconnaissance Satellites (TRACERS) Mission. Mission design is described in The Tandem Reconnection and Cusp Electrodynamics Reconnaissance Satellites (TRACERS) Mission Design, while  From the TRICE-2 Investigations to the TRACERS Mission shows how a the results of 2018 sounding rocket mission guided the science objectives of the TRACERS mission.

    The articles describing instrumentation include: 

    The article Observing Cusp High-Altitude Reconnection and Electrodynamics: The TRACERS Student Rocket describes the Observing Cusp High-altitude Reconnection and Electrodynamics (OCHRE) mission, a student/early career researcher (ECR) focused sounding rocket that will fly as a compliment to the TRACERS satellites. The launch is scheduled in Winter 2026 from Andøya, Norway.

    Miles expects additional articles to be published in the collection as the mission progresses.

    The TRACERS mission is a collaborative effort involving the University of Iowa, Southwest Research Institute, UCLA, UC Berkeley, and Millennium Space Systems. It is dedicated to the late Professor Craig Kletzing, the mission’s original Principal Investigator and a longtime leader in space plasma research at Iowa.

    TRACERS continues the department’s legacy of leadership in space physics and instrumentation and represents a major step forward in understanding the fundamental processes that shape space weather and Earth’s near-space environment. 

     

    Continue Reading